Olanzapine API

Name	Olanzapine
Chinese name	奥氮平
Cas Number	132539-06-1
Source	India
Qualifications	USDMF/-/-/-/-

Olanzapine was developed by Eli Lilly and was first marketed in the United States in 1996. It is the first atypical antipsychotic approved for the long-term treatment of schizophrenia and the first approved for the treatment of acute bipolar mania Atypical antipsychotic drugs. Olanzapine can bind to dopamine receptors, 5-HT receptors and cholinergic receptors, and has an antagonistic effect. Antagonizing the D2 receptor is related to the treatment of positive symptoms of schizophrenia; antagonizing the 5-HT2A receptor is related to the treatment of negative symptoms of schizophrenia. Unlike clozapine, olanzapine does not cause agranulocytosis, no delayed disorder and severe symptoms of neurosis. Taking drug withdrawal as an effect indicator, olanzapine is more effective than other antipsychotic drugs. As a new type of antipsychotic drug, Olanzapine has the advantages of good long-term efficacy and low side effects. It is highly recognized by clinicians. Olanzapine is currently the first-line drug for global antipsychotic treatment and is recognized by the international psychiatric community as the most ideal new type so far. Antipsychotics. In 2019, China's olanzapine market reached 4.089 billion yuan, with a market growth rate of 4.17%.

Hot Tags: olanzapine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Idebenone API, Lapatinib Ditosylate API, Valganciclovir Hydrochloride API, Letrozole API, Teriflunomide API, Paliperidone API

• Previous: Afatinib Maleate API
• Next: Buspirone API